Daniel J. Kenan

Daniel J. Kenan

Auto-generated profile, based on publicly available information

Daniel J. Kenan

Arkana Laboratories, Little Rock, Arkansas

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
ARAlejandro Best Rocha
Alejandro Best Rocha
ESEdana Stroberg
Edana Stroberg
LBLisa M. Barton
Lisa M. Barton
EDEric J. Duval
Eric J. Duval
SMSanjay Mukhopadhyay
Sanjay Mukhopadhyay
CLChristopher P. Larsen
Christopher P. Larsen

26 August 2021 in Kidney360
Verified
Journal Article
Closed access
PDF file
TCTiffany Caza
Tiffany Caza
SHSamar I. Hassen
Samar I. Hassen
DKDaniel J. Kenan
Daniel J. Kenan
ASAaron Storey
Aaron Storey
JAJohn M. Arthur
John M. Arthur
CLChristopher P. Larsen
Christopher P. Larsen
Key Points: TGF-β receptor 3 (TGFBR3) staining identifies a novel type of membranous nephropathy (MN). TGFBR3-associated MN is enriched in patients with membranous lupus nephritis with similar characteristics as exostosin 1/2- and neural cell adhesion molecule 1–associated MN. Identification of TGFBR3-associated MN should alert the clinician to evaluate for underlying autoimmune disease. Background: Membranous lupus nephritis (MLN) comprises 10%–15% of lupus nephritis and increases morbidity and mortality of patients with SLE through complications of nephrotic syndrome and chronic kidney failure. Identification of the target antigens in MLN may enable noninvasive monitoring of disease activity, inform treatment decisions, and aid in prognostication, as is now possible for idiopathic MN caused by antibodies against the phospholipase A2 receptor. Here, we show evidence for type III TGF-β receptor (TGFBR3) as a novel biomarker expressed in a subset of patients with MLN. Methods: Mass spectrometry was used for protein discovery through enrichment of glomerular proteins by laser capture microdissection and through elution of immune complexes within MLN biopsy specimens. Colocalization with IgG within glomerular immune deposits from patients and disease controls was evaluated by confocal microscopy. Immunostaining of consecutive case series was used to determine the overall frequency in MN and MLN. Results: TGFBR3 was found to be enriched in glomeruli and coimmunoprecipitated with IgG within a subset of MLN biopsy specimens by mass spectrometry. Staining of consecutive MN cases without clinical evidence of SLE did not show TGFBR3 expression (zero of 104), but showed a 6% prevalence in MLN (11 of 199 cases). TGFBR3 colocalized with IgG along the glomerular basement membranes in TGFBR3-associated MN, but not in controls. Conclusions: Positive staining for TGFBR3 within glomerular immune deposits represents a distinct form of MN, substantially enriched in MLN. A diagnosis of TGFBR3-associated MN can alert the clinician to search for an underlying autoimmune disease.

1 June 2017 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DKD. J. Kenan
D. J. Kenan
PMPiotr Mieczkowski
Piotr Mieczkowski
ELE. Latulippe
E. Latulippe
ICI. Côté
I. Côté
HSH. K. Singh
H. K. Singh
Volker NickeleitVolker Nickeleit
Volker Nickeleit
Human polyomaviruses are ubiquitous, with primary infections that typically occur during childhood and subsequent latency that may last a lifetime. Polyomavirus-mediated disease has been described in immunocompromised patients; its relationship to oncogenesis is poorly understood. We present deep sequencing data from a high-grade BK virus–associated tumor expressing large T antigen. The carcinoma arose in a kidney allograft 6 years after transplantation. We identified a novel genotype 1a BK polyomavirus, called Chapel Hill BK polyomavirus 2 (CH-2), that was integrated into the BRE gene in chromosome 2 of tumor cells. At the chromosomal integration site, viral break points were found, disrupting late BK gene sequences encoding capsid proteins VP1 and VP2/3. Immunohistochemistry and in situ hybridization studies demonstrated that the integrated BK virus was replication incompetent. We propose that the BK virus CH-2 was integrated into the human genome as a concatemer, resulting in alterations of feedback loops and overexpression of large T antigen. Collectively, these findings support the emerging understanding that viral integration is a nearly ubiquitous feature in polyomavirus-associated malignancy and that unregulated large T antigen expression drives a proliferative state that is conducive to oncogenesis. Based on the current observations, we present an updated model of polyomavirus-mediated oncogenesis.

2 June 2025 in Kidney360
Verified
Journal Article
Open access
RHRandy S. Haun
Randy S. Haun
CLChris P. Larsen
Chris P. Larsen
JWJon D. Wilson
Jon D. Wilson
DKDaniel J. Kenan
Daniel J. Kenan
Background: Approximately 13% of African Americans have a combination of risk variants of the APOL1 gene, often termed the APOL1 “high-risk genotype", which predisposes individuals to serious kidney diseases such as focal segmental glomerulosclerosis. Despite the potential severity of APOL1-linked kidney disease, genetic testing for APOL1 variants is uncommonly performed. Point-of-care testing has the potential to be transformative in patient care to immediately identify risk status, particularly for the evaluation of deceased donor organs in the setting of transplantation, but no assays are available to date. Methods: To begin to address this unmet need, we developed a CRISPR-Cas12a-mediated genotyping assay for the detection of pathological APOL1 variants from patient samples for potential use in a point-of-care setting. For each variant, crRNA guides were identified that could readily discriminate between either the 'wild-type' or variant sequence in a Cas12a-trans-cleavage assay using both fluorescence- and lateral flow-based detection methods. Results: Interestingly, no protospacer-adjacent-motif (PAM) sequence was required for the CRISPR-Cas12a-based detection of any of the variants. CRISPR-Cas12a fluorescence-based genotyping assays performed on patient samples achieved 100% sensitivity and specificity compared to genotypes obtained using a clinically-validated TaqMan assay. Similar results were also obtained in lateral flow assay format with a FAM- and biotin-labeled reporter. Conclusions: The successful deployment in this study of Cas12a-based assays to generate APOL1 genotypes for individuals with high fidelity provides promise for a genotyping method potentially amenable to point-of-care use.